Kornimate/medical-research-clean huggingface dataset:
hemiarthroplasty or internal fixation for displaced femoral neck fractures

Conditions: Femoral Neck Fractures

Summary: an estimated 1.6 million patients sustain a hip fracture every year, about half of these are intracapsular femoral neck fractures. a femoral neck fracture is a life changing event for any patient, and the risk of disability, increased dependence and death is substantial. the main treatment options for displaced femoral neck fractures are internal fixation and arthroplasty. it is established that there are more complications and reoperations after internal fixation, but there is no consensus about which procedure that gives best functional results.

we plan to include patients with displaced intracapsular femoral neck fractures. the patients will be randomized by means of closed numbered envelopes to operation groups: 1. two parallel screws (olmed). 2. hemiarthroplasty with charnley/ hastings prosthesis. a priori one would expect that there would be less morbidity and mortality with the less extensive and quicker operation with parallel screw and that a faster and better rehabilitation would be achieved with hemiarthroplasty.

Eligibility criteria:
inclusion criteria: * displaced femoral neck fracture * age 60 or above * able to walk (any aids allowed) exclusion criteria: * anesthesiologically unfit for arthroplasty surgery * previous symptomatic hip pathology (i.e. arthritis) * pathological fracture * delay of more than 96 hours from injury to treatment * not living in hospital area

Keywords: displaced femoral neck fractures treatment function pain quality of life complications reoperations internal fixation hemiarthroplasty activities of daily living
etanercept plus uvb-311nm phototherapy in psoriasis

Conditions: Psoriasis

Summary: etanercept, a biological antipsoriatic drug with anti-tumor-necrosis factor (tnf) activity has been approved for the treatment of moderate to severe psoriasis. however, in a substantial portion of cases etanercept does not induce reduction in psoriasis area and severity index (pasi) of 75% or greater, now being considered as gold standard for treatment efficacy. in this study the researchers aim to determine in a randomized half-side comparison, whether additional narrowband uvb-311nm phototherapy accelerates and improves the therapeutic efficacy of etanercept.

patients with moderate to severe psoriasis who have received a standard dose of etanercept (50 mg or 25 mg s.c. twice weekly) for at least 6 weeks without a pasi reduction of 75% or greater qualify for the study. etanercept is continued and uvb-311nm phototherapy is added at 6 weeks or thereafter on a randomized body half (left or right; head exempt) 3 x per week until complete response (defined as reduction in pasi to \ 90%, \> 75%, and/or 50% between body sites.

Eligibility criteria:
inclusion criteria: * patients with moderate to severe psoriasis who have received a standard dose of etanercept (50 mg or 25 mg s.c. twice weekly) for at least 6 weeks without a pasi reduction of 75% or greater exclusion criteria: * pregnancy or lactation * presence of or history of malignant skin tumors * dysplastic melanocytic nevus syndrome * antinuclear antibodies (ds-dna, ro/ssa, la/ssb) * autoimmune disorders such as lupus erythematosus or dermatomyositis * photosensitive diseases such as porphyria, chronic actinic dermatitis, xeroderma pigmentosum, basal cell nevus syndrome, and others * general poor health status

Keywords: psoriasis uvb radiation biologics etanercept pasi
study to evaluate the long-term safety and efficacy of abt-335, in combination with three different statins in subjects with mixed dyslipidemia.

Conditions: Dyslipidemia; Coronary Heart Disease; Mixed Dyslipidemia

Summary: the primary purpose of this study is to test the safety and the effects of using an investigational drug regimen; once daily abt-335 (investigational drug) administered in combination with once daily atorvastatin calcium, rosuvastatin calcium or simvastatin in patients with abnormal lipid levels in the blood.


Eligibility criteria:
inclusion criteria: * adult male and female subjects who voluntarily sign the informed consent. * subject has successfully completed one of the three abt-335, rosuvastatin, simvastatin and atorvastatin combination therapy studies. exclusion criteria: * subject is using or will use investigational medications, except as approved by abbott. * subject has prematurely discontinued his/her initial therapy one of the prior abt-335, rosuvastatin, simvastatin and atorvastatin calcium combination therapy studies.
a study of avastin (bevacizumab) and irinotecan versus temozolomide radiochemistry in patients with glioblastoma

Conditions: Glioblastoma Multiforme

Summary: this 2 arm study will compare the effect of avastin + irinotecan versus temozolomide, in combination with conventional involved field radiotherapy, in patients with newly diagnosed glioblastoma and a non-methylated mgmt promoter. patients will be randomized 3:1 to receive avastin 10mg/kg iv every 2 weeks + irinotecan 125mg/m2 iv every 2 weeks, or temozolomide 75mg/m2 po daily during radiotherapy followed by 6 cycles of temozolomide 150-200mg/m2 po daily on days 1-5 of each 4 week cycle. the anticipated time on study treatment is until disease progression, and the target sample size is 100-500 individuals.


Eligibility criteria:
inclusion criteria: * adult patients, 18-70 years of age; * glioblastoma, confirmed histologically; * no previous chemotherapy or radiotherapy for glioblastoma; * non-methylated mgmt promoter in the tumor. exclusion criteria: * prior systemic treatment for glioblastoma multiforme; * prior treatment with avastin; * significant cardiovascular disease; * other active malignant disease.
mesh fixation with a synthetic glue in primary inguinal hernia repair

Conditions: Inguinal Hernia

Summary: prospective observational study with mesh fixation using fda approved synthetic glue,glubran 2 and standard mesh fixation with stiches in primary inguinal hernia repair surgery. the investigators aim is to recruit 150 patients for the study. the outcomes the investigators would like to determine are : postoperative pain,recurrences and complication rates such as seromas.

prospective observational study with mesh fixation using fda approved synthetic glue,glubran 2 and standard mesh fixation with stiches in primary inguinal hernia repair surgery. the investigators aim is to recruit 150 patients for the study. the outcomes the investigators would like to determine are : postoperative pain,recurrences and complication rates such as seromas.

Eligibility criteria:
inclusion criteria: * primary inguinal hernia exclusion criteria: * recurrent hernia * large inguinoscrotal hernias * bilateral inguinal hernias
pilot study to evaluate the safety and efficacy of ariva® silver wintergreen in reducing cigarette craving in smokers

Conditions: Tobacco Use Disorder; Smoking

Summary: study to determine the safety and effectiveness of ariva® silver wintergreen lozenge on reducing craving for a cigarette in daily smokers.

each subject will be given an ariva® silver wintergreen lozenge or a silver wintergreen lozenge, which contains only silver salt, on a random basis. once the lozenge has dissolved in the mouth, subjects will smoke one of their own cigarettes, and will answer questions about the experience and their craving for a cigarette. after a washout period, each subject will repeat the steps with the second type of lozenge.

Eligibility criteria:
inclusion criteria: * healthy adult smoker * smoking for at least 5 years * smoking at least one (1) pack of cigarettes a day * interest in quitting smoking exclusion criteria: * known allergy to silver or silver salts * pregnant or breast-feeding * current drug or alcohol abuse, and/or history of drug or alcohol dependence within 3 months of study

Keywords: smoking smokeless aversion nicotine nicotine replacement
intravenous dexmedetomidine for cesarean section

Conditions: Breast Feeding; Analgesia Obstetrical; Postoperative Pain

Summary: nervous, anxiety, fear and other psychological reactions always appears in parturients during cesarean section. this study intends to investigate the effectiveness and safety of dexmedetomidine combined with butorphanol tartrate for postoperative analgesia and breastfeeding after caesarean section.


Eligibility criteria:
inclusion criteria: 1. parturients who had successfully breastfed a prior infant and planned to breastfeed after this delivery were screened for eligibility. 2. parturients undergoing elective caesarean delivery under epidural anaesthesia 3. asa i and ii parturients aged 18-45 years, with singleton gestation. 4. parturients with verbal and written mandarin 5. parturients who want to use pca intravenous analgesia and can use the pump correctly 6. written informed consent. exclusion criteria 1. multiple gestation. 2. a history of allergy to dexmedetomidine or other study drugs 3. cardiovascular disease (basic hr\<50bpm or sbp\<100mmhg) 4. opioid drugs abuse. 5. bmi more than 35 kg/m2 6. conditions that preclude spinal anesthesia. 7. preeclampsia or epilepsy. 8. a history of neuromuscular disease. 9. epidural anaesthesia was unsuccessful. 10. the parturients, whose surgery ended after 11 a.m.

Keywords: dexmedetomidine butorphanol tartrate analgesia breastfeeding relative infant dose
clinical study of car-t cell therapy following asct for r/r b-cell non-hodgkin's lymphoma

Conditions: Lymphoma, B-Cell; Autologous Stem Cell Transplantation

Summary: the study is designed to evaluate the efficacy and safety of chimeric antigen receptor t-cell therapy following autologous stem cell transplantation for relapsed/refractory b-cell non-hodgkin's lymphoma.

chimeric antigen receptor t (car-t) cell therapy has emerged as a promising approach for relapsed or refractory b-cell non-hodgkin's lymphoma (r/r b-nhl), with a complete response (cr) rate of about 50%. it is also considered to be a reasonable consolidation option in low or unmeasurable disease states recently. unfortunately, 40%-70% of patients experienced relapse after car-t cell therapy in the long-term follow up. autologous stem cell transplantation (asct) with myeloablative chemotherapy can enhance the efficiency of car-t cells and alleviate tumor load, leading to a lower relapse rate. as a result, car-t cell therapy following asct may be a promising method for r/r lbcl patients.

Eligibility criteria:
inclusion criteria: 1. age: 18-65 years. 2. pathological immunohistochemistry or flow cytometry confirmed that r/ r large b-cell non-hodgkin's lymphoma with measurable (the longest diameter greater than 1.5cm and the longest vertical diameter greater than 1.0cm) lesions. 3. previously treated with 1 or more lines of therapy. 4. ecog≤2#. 5. the main organ functions need to meet the following conditions:lvef≥50%;ccr≥30 ml/min; alt and ast≤3 times normal range. 6. hematopoietic function needs to meet the following conditions: platelet count≥45×10\^9/l; hemoglobin≥8.0 g/dl; absolute neutrophil count≥1.0×10\^9/l. 7. subjects of child-bearing or child-fathering potential must be willing to practice birth control from the time of enrollment on this study until the follow-up one year period of the study. 8. estimated survival time ≥3 months. 9. voluntary signing of informed consent and good compliance. exclusion criteria: 1. have used immunosuppressants or hormones within 2 weeks prior to apheresis, or have to use immunosuppressants or hormones after signing informed consent. 2. the presence of bacterial, fungal, viral, mycoplasma or other types of infection that, in the judgment of the investigator, are difficult to control. 3. active hepatitis b or active hepatitis c. 4. hiv infection. 5. have received car-t cell therapy or allogeneic hematopoietic stem cell transplantation prior to signing the informed consent. 6. prior malignancy (other than relapsed refractory b-cell non-hodgkin's lymphoma). 7. pregnant or breasting-feeding women. 8. there is evidence of complications or medical conditions that could interfere with the conduct of the study or put patients at serious risk, including but not limited to serious cardiovascular disease. 9. conditions deemed by the researchers to be inappropriate for participation.

Keywords: relapsed/refractory b-cell non-hodgkin's lymphoma car-t cell therapy autologous stem cell transplantation
pmcf study for partial vision restoration using the subretinal implant retina implant alpha ams

Conditions: Retinitis Pigmentosa

Summary: this study is a post-market clinical follow-up (pmcf) study to monitor the safety, lifetime and efficacy of patients using the ce-certified retina implant alpha ams.

this study is a post-market clinical follow-up (pmcf) study to monitor the safety, lifetime and efficacy of patients using the ce-certified retina implant alpha ams. for germany, it is under the exceptions mentioned in §23b mpg (medizinproduktegesetz, german medical device law). its purpose is to collect data that is created during the regular therapy with the implant. no additional examinations are performed, except a patient questionnaire.

Eligibility criteria:
inclusion criteria: * patients who received a retina implant alpha ams. * patients willing and able to give written informed consent. exclusion criteria: * none
itv extension study

Conditions: HIV

Summary: the objective of this phase i/ii therapeutic human immunodeficiency virus (hiv) vaccine candidate study is to provide proof of concept for a hiv antigen delivery system in terms of safety, virological effects and selected immune responses in hiv infected individuals after cessation of antiretroviral combination therapy (art).

a multi-centre, double-blind, placebo-controlled, 20-week parallel group extension study to the vir-nchr-01 protocol (itv study). the purpose of the extension study is to assess the safety and virological effects of a therapeutic hiv vaccine strategy in hiv-1 infected adults currently enrolled in the itv study after cessation of antiretroviral therapy. two active candidate vaccines will be studied in this trial: the active treatment arms will receive recombinant fowlpoxvirus (rfpv) expressing hiv gag-pol antigens or hiv gag-pol antigens and interferon-gamma (ifn-y) in diluent. vaccines will be delivered by intramuscular injection.

Eligibility criteria:
inclusion criteria: * hiv-1 infected individuals eligible and still fulfilling the criteria for the vir-nchr-01 protocol (itv study) * received all 3 immunisations * remained in follow-up for at least 52 weeks * continued to take combination antiretroviral therapy with no evidence of treatment failure at the time entering the roll-over phase * written informed consent obtained criteria for withdrawal of study participants * incidental or progression of disease which, in the opinion of the principal investigator, should preclude further study participation * if the study participant required cytotoxic or immunosuppressive chemo- or radiation therapy * if the study participant required any medications that when combined with the study vaccination, would in the opinion of the principal investigator, jeopardise the validity of the individual's continued participation * administration of prohibited alternative therapy * study participant non-compliance * all study participants are required to adhere to the protocol evaluation schedule. failure to adhere with this schedule without having first provided justification may result in the participant being withdrawn from the study * at the request of the study participant or principal investigator without prejudice to future health care * in the opinion of the investigator, if it is not in the patient's best interests to continue the study * at the request of the national centre in hiv epidemiology and clinical research (nchecr) with reasonable cause * at the advice of the data safety monitoring board (dsmb)

Keywords: hiv therapeutic vaccine
framingham children's study - food and exercise habits in framingham study descendents

Conditions: Cardiovascular Diseases; Heart Diseases

Summary: to identify early childhood determinants of eating and exercise behaviors that relate to cardiovascular disease.

background: while dietary and physical activity habits are known to relate to cardiovascular risk, in 1985 little data were available on factors that influence the development of such behaviors early in life. in 1987, 106 families with 3 to 5 year old children were recruited to take part in the framingham children's study. the children and their parents are direct descendents (4th and 3rd generation, respectively) of participants in the framingham heart study. during the initial grant period, the feasibility of collecting relevant data has been demonstrated. maintenance of the cohort and acceptance of the monitoring procedures have been excellent, due partly to the fact that the families consider themselves a part of the framingham heart study and take pride in long-term compliance with study procedures. design narrative: the investigators have been following 100 families who are 3rd and 4th generation descendants of the original framingham heart study cohort. the subjects were age 3-5 years at the onset of the study and were ages 11-14 years in 1996. there has been excellent cohort maintenance with over 90 percent of the original families continuing to participate. the study was renewed in fy 1996 to extend the framingham children's study (fcs) to permit the evaluation of the determinants of change in the child's risk behaviors and other risk factors from early childhood through puberty to mid to late teens, a time when the individual's risk profile should better reflect his/her cardiovascular risk status as an adult. the fcs is a longitudinal source of data on diet, activity and family and environmental factors in children. by 1996, the investigators had collected extensive dietary data with an average of 32 days of diet records and almost 50 days of electronically monitored physical activity data for each subject. additional data included psychosocial and anthropometric data on children and their parents. the extension of the fcs allows continued monitoring of eating behaviors and physical activity habits of the children and their parents, as well as the personal environmental and behavioral factors influencing changes in the child's physical activity, diet, blood pressure, lipids and obesity from pre-school into the late teen years. the study completion date listed in this record was obtained from the "end date" entered in the protocol registration and results system (prs) record.

Eligibility criteria:
no eligibility criteria
cardiovascular response in implant surgery

Conditions: Dental Anxiety; Cardiovascular Abnormalities

Summary: the aim of this study was to observe the level of anxiety and its relationship with cardiovascular changes in each implant.


Eligibility criteria:
inclusion criteria: * over 30 * 4 years and older implant in the same session exclusion criteria: * patients with syndrome, * having systemic disease, * having heart problems, * undergo another oral or maxillofacial procedure in the last 6 months, * using medications that may cause changes in medical conditions and heart rate,
open inguinal hernia repair with mesh,the use of absorbable versus non absorbable fixation sutures

Conditions: Inguinal Hernia

Summary: the purpose of this study is to determine the efficacy of mesh fixation using absorbable versus non-absorbable sutures.


Eligibility criteria:
inclusion criteria: * all patients undergoing initial unilateral open inguinal hernia repair surgery. exclusion criteria: * patients having repeated inguinal hernia or bilateral hernia * patients undergoing laparoscopic surgery.

Keywords: absorbable sutures efficacy reducing adverse effect to be caused from surgery inguinal hernia repair with mesh
nursing interventions for alzheimer's patients during pet/ct imaging

Conditions: Alzheimer's Disease

Summary: the impact of nursing interventions during pet/ct imaging in alzheimer's patients on image quality and patient satisfaction will be assessed in 200 patients.

this study will analyze clinical data from 200 alzheimer's disease (ad) patients who underwent pet imaging and were admitted to sichuan provincial people's hospital over a period of six months. the control group will receive routine nursing intervention, while the observation group will receive a refined specialized nursing intervention. we will meticulously compare various performance aspects in both groups to assess the impact of refined specialized nursing intervention on patients' image quality and patient satisfaction.

Eligibility criteria:
inclusion criteria: * meet the criteria for diagnosing dementia as described in the fourth edition of the diagnostic and statistical manual of mental disorders (dsm-iv-r), use the diagnostic criteria for ad from the national institute of neurology, speech and communication disorders and stroke - alzheimer's disease and related disorders (nincds-adrda) or the national institute on aging and alzheimer's disease association (nia-aa). exclusion criteria: * patients with a history of stroke and focal neurological signs, and imaging findings consistent with small cerebral vascular disease (fazekas score ≥2); * the presence of other neurological disorders that can cause brain dysfunction (e.g., depression, brain tumors, parkinson's disease, metabolic encephalopathy, encephalitis, multiple sclerosis, epilepsy, brain trauma, normal facial pressure hydrocephalus); * the presence of other systemic diseases that can cause cognitive impairment (such as liver insufficiency, renal insufficiency, thyroid dysfunction, severe anemia, folic acid or vitamin b12 deficiency, syphilis, hiv infection, alcohol and drug abuse, etc.); * there is mental and neurological retardation. * there are other diseases that are known to cause cognitive impairment.
postpartum hemorrhage prevention in patients with preeclampsia (php3 study)

Conditions: Preeclampsia

Summary: evaluation of the efficacy of postpartum 24 hour oxytocin infusion to reduce blood loss in patients with pre-eclampsia (pe)

the overall goal of this study is to evaluate the efficacy of postpartum 24 hour oxytocin infusion as a prevention-oriented strategy to reduce blood loss in patients with pre-eclampsia (pe) in a blinded, placebo controlled, randomized controlled trial.

Eligibility criteria:
inclusion criteria: 1. vaginal or cesarean delivery at a gestational age greater than or equal to 20 weeks gestational age; 2. diagnosis of preeclampsia (pe defined using standard definitions based on the acog bulletin and the nih working group on high blood pressure in pregnancy (i.e., a systolic blood pressure greater than 140 mm hg or a diastolic blood pressure greater than 90 mm hg on at least 2 occasions at least 6 hours apart after 20 weeks gestation and proteinuria of \> 300mg per 24 hour period or \> 1+ on dipstick). 3. patients treated with magnesium sulfate for 24 hours post partum at 2g/hr (standard of care when deemed appropriate by clinician for seizure prophylaxis) exclusion criteria: 1. abnormal placentation (previa, accreta, etc) 2. antenatal hemorrhage 3. contraindication to oxytocin